Brightpath Biotherapeutics received FDA IND clearance for BP-2202, enabling the start of a first-in-human phase I trial in relapsed or refractory multiple myeloma. The company said dosing will begin later this year, following the regulatory milestone. The clearance positions BP-2202 for early clinical evaluation of safety, tolerability and preliminary anti-tumor activity in a treatment-refractory setting. IND approval also gives Brightpath the runway for site activation and patient recruitment planning. For developers, this is a near-term de-risking event that converts a discovery-stage program into a clinical dosing timeline.